Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 30 Matches

Amodiaquine

Model Files Publication

Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	CYP2C8 = 72%; Additional HLM = 28%
Perpetrator DDI	CYP2D6
Validation	Four clinical studies describing single and multiple dose exposure of amodiaquine were used to verify the PBPK model. In comparison of predicted vs. observed AUC, 75% of the studies were 2-fold and 50% were within 1.5-fold. A clinical DDI study where amodiaquine was the victim of a CYP2C8-mediated DDI was accurately recovered using the PBPK model.
Limitations	Clinical data has not been used to verify amodiaquine as a perpetrator of CYP2D6-mediated DDIs
Updates in V19	Updated in vitrodata fu: 0.033 -> 0.089 B:P: 1.3 -> 1.1 DEAQ Ki for CYP2D6 (µM) – 1.7 -> 1.6 Converted from minimal PBPK model to full PBPK model Recalculated retrograde clearance for CYP2C8 CL_int and additional HLM CL_int

Search Score: 1

Cidofovir_V12R1_FDA_20150709

Model Files Publication

Table 1 of main text, further discussion in supplemental file. Clarification: the value of intrinsic CL for hepatic elimination (0.41) is for undefined human liver microsomes according to retrograde calculation, with a unit of uL/min/mg. The operating hepatic CLint is driven by S9, which has a value of 0.13, obtained from sensitivity analysis to match HLM value above. This clarification will be informed to the journal.

Search Score: 1

Nicotine_MechKiM_V16R1_UniversityOfManchester_20210421

Model Files Publication

https://doi.org/10.1124/jpet.118.251413 Nicotine compound file with MechKiM

Search Score: 1

Digoxin_V12R2_Simcyp_20150702

Model Files Publication

For the file, ADAM and permeability-ltd liver models were used together with the full-PBPK and Rodgers and Rowland method. The file was evaluated using the Jalava et al. 1997 PK data as overlay.

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Amodiaquine

The model at-a-glance

Cidofovir_V12R1_FDA_20150709

Nicotine_MechKiM_V16R1_UniversityOfManchester_20210421

Digoxin_V12R2_Simcyp_20150702

Your Privacy